Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsMEPDF 81 3-Year EBITDA Growth Rate is 7.40% as of Mar. 2026, which is at its 10-year median of 7.40. GuruFocus rates MEPDF with a GF Score™ of 81/100 and a GF Value™ of $17.73 (Fairly Valued). The stock has 3 warning signs investors should review. Among 105 Medical Distribution companies, Medipal Holdings ranks better than 55.24% on this metric.
During the past 12 months, Medipal Holdings's average EBITDA Per Share Growth Rate was 7.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 4.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medipal Holdings was 40.20% per year. The lowest was -25.30% per year. And the median was 7.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medipal Holdings 3-Year EBITDA Growth Rate Related Terms
MEPDF vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Medipal Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.40% mean?
Medipal Holdings (MEPDF) has a 3-Year EBITDA Growth Rate of 7.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medipal Holdings and its competitors. This is near median its historical median of 7.40. According to the industry distribution chart, Medipal Holdings ranks #47 out of 105 companies in the Medical Distribution industry, placing it in the top 44.8%.
Is Medipal Holdings' 3-Year EBITDA Growth Rate too high?
Medipal Holdings' current 3-Year EBITDA Growth Rate of 7.40% is near median its 10-year median of 7.40. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 5.40. Medipal Holdings' value of 7.40% is 37% above this industry median. Based on the distribution chart, Medipal Holdings ranks #47 out of 105 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medipal Holdings has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #47 out of 105 companies for 3-Year EBITDA Growth Rate. This puts Medipal Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 5.40. Medipal Holdings' value of 7.40% is 37% above this benchmark. While the company's 10-year median is 7.40 vs. the industry median of 5.40, Medipal Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.40, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current 3-Year EBITDA Growth Rate of 7.40% is 37% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medipal Holdings and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current 3-Year EBITDA Growth Rate is 7.40%, which is near median its own 10-year median of 7.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MEPDF) is currently considered Fairly Valued. The stock's GF Value™ is $17.73, compared to a current price of $18.35 — trading 3.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.40%, which is near median its 10-year median of 7.40 and 37% above the Medical Distribution industry median of 5.40. Medipal Holdings' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medipal Holdings (MEPDF), the current 3-Year EBITDA Growth Rate is 7.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MEPDF) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of $18.35 is trading 3.5% above its estimated GF Value™ of $17.73.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for MEPDF:
3-Year EBITDA Growth Rate: 7.40% (near median its 10-year median of 7.40)
GF Value™: $17.73 vs. price of $18.35 (3.5% above fair value)
Industry Position: 37% above the Medical Distribution median (#47 of 105)
No single metric tells the full story. See the MEPDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
81GF Score
Get the complete analysis for MEPDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEPDF has been successfully added to your 
